News summary produced by Claude AI
Defense Secretary Pete Hegseth unveiled a testosterone screening initiative on Wednesday, establishing annual testing as part of routine medical evaluations for military personnel aged 30 and older, with participation voluntary for younger service members. Hegseth stated in a video announcement that testosterone replacement therapy would remain optional and framed the program as necessary to maintain troop readiness and operational capability.
The policy announcement aligns with broader Trump administration efforts to increase access to testosterone replacement therapies. Other administration officials, including Health Secretary Robert F. Kennedy Jr., have pursued regulatory changes to expand testosterone prescribing. Last month, the Food and Drug Administration proposed loosening restrictions on testosterone gels, pills, patches and injections, which are currently approved only for men with hypogonadism, a condition causing severely low hormone levels.
The Pentagon declined to specify which research or studies supported the policy decision and did not address whether female service members would receive comparable evaluations for estrogen-based therapy. Medical experts have long debated appropriate testosterone testing and treatment protocols, with current guidelines generally recommending against routine screening absent specific symptoms and documented low levels confirmed through multiple blood tests. The military has faced previous challenges related to hormone use, including investigations into performance-enhancing substance use among Navy SEAL special operations personnel and a 2022 recruit death that revealed widespread drug use within the elite program.
The announcement drew criticism from Rep. Chrissy Houlahan, a Pennsylvania Democrat and Air Force veteran, who questioned whether testosterone resources would be equitably available to both male and female service members. Houlahan noted that Hegseth has previously opposed women in combat roles and has taken actions affecting female military personnel promotions and leadership positions since assuming office.
Hegseth emphasized the initiative is not intended for artificial performance enhancement. Recent medical research has produced mixed findings regarding testosterone benefits, with some studies showing improvements in sexual function and mood for certain populations, while demonstrating minimal effects on fatigue and cognitive function. The FDA previously removed safety warnings about cardiovascular risks from testosterone medications.